A carregar...
Afatinib in advanced NSCLC: a profile of its use
Afatinib [Giotrif(®) (EU); Gilotrif(®) (USA)] is an orally administered, irreversible inhibitor of the ErbB family of tyrosine kinases that provides an important first-line treatment option for advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutati...
Na minha lista:
| Publicado no: | Drugs Ther Perspect |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer International Publishing
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5840214/ https://ncbi.nlm.nih.gov/pubmed/29540977 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40267-018-0482-6 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|